Colorectal cancer research surges at Vanderbilt-Ingram Cancer Center

July 26, 2007

The Vanderbilt-Ingram Cancer Center has landed another round of support for its Specialized Program of Research Excellence (SPORE) in gastrointestinal cancer, one of only five such programs in the country. The National Cancer Institute will provide $11.8 million over the next five years to forward Vanderbilt-Ingram's innovative colorectal cancer research.

"We received the top score in the country in the latest pool of GI SPORE applications," said Robert J. Coffey Jr., M.D., Ingram Professor of Cancer Research, Wallace Professor of Medicine, and director of the GI SPORE. "This reflects that we have one of the premier GI cancer programs in the country here at Vanderbilt."

The NCI established organ-specific SPOREs in 1992 to promote interdisciplinary research with a "translational" emphasis -- work that spans the gap from basic science discovery to clinical application. SPOREs bring together basic, clinical and population-based scientists to collaborate on research with clear potential to improve patient care. GI SPOREs are located at Vanderbilt, Johns Hopkins University, Harvard University, the University of Arizona and the University of North Carolina at Chapel Hill.

Vanderbilt-Ingram has two additional SPOREs, one in breast cancer and one in lung cancer. It is one of only seven centers to hold three or more SPORE grants.

Vanderbilt's GI SPORE, co-directed by Mace Rothenberg, M.D., focuses on colorectal cancer, the second leading cancer killer in the United States. There will be nearly 150,000 new cases of colorectal cancer diagnosed this year and more than 55,000 deaths, according to American Cancer Society estimates. And because the risk of developing colorectal cancer grows with age, the impact of this cancer is expected to increase as the U.S. population ages.

Coffey attributes Vanderbilt's success in colorectal cancer research to a "very strong three-pronged approach." One prong, the Epithelial Biology Program, focuses on polarized colorectal cancer cells in vitro -- how they compartmentalize important signaling molecules like the epidermal growth factor (EGF) receptor and some of its ligands.

Insights from cells are advanced to mouse models in the second prong -- Vanderbilt is a member of the NCI's Mouse Models of Human Cancers Consortium (MMHCC) -- and to human beings studied as part of the GI SPORE in the third prong. Coffey is the only person in the country to direct both an MMHCC and a SPORE grant.

"We have created a robust platform to propel forward innovative diagnostic and therapeutic approaches to colorectal cancer," Coffey said.

In the GI SPORE's first five-year cycle, Vanderbilt investigators made significant progress, Coffey noted. They implicated altered regulation of p120 -- a protein first identified at Vanderbilt -- in the pathogenesis of colorectal cancer, conducted a biomarker-based cooperative group trial of Iressa in the treatment of advanced colorectal cancer, and initiated a large population-based study examining predictors of adenoma (colon polyp) recurrence.

The renewal application for the GI SPORE includes continuing projects from the first cycle and a new high-throughput screening strategy that aims to develop drug candidates for treating colorectal cancer.

"We knew that the competition was going to be intense, so we decided to â€Ëœroll the dice' and propose high-risk, high-payoff projects," Coffey said. "We are the first SPORE to propose high-throughput screening."

The investigators are using the Vanderbilt Institute of Chemical Biology's high-throughput screening facility under the direction of C. David Weaver, Ph.D., to screen libraries of synthetic small molecules and natural products. R. Daniel Beauchamp, M.D., is leading a screen for compounds that restore E-cadherin to the cell surface of colorectal cells and could therefore reverse the epithelial-to-mesenchymal transition that is a central event in the development of metastasis. Ethan Lee, M.D., Ph.D., is directing a screen to identify agents that block Wnt signaling, a pathway that becomes deranged in nearly 90 percent of colorectal cancers.

"We already have a number of exciting hits from these screens," Coffey said. One of the "hits" is an FDA-approved drug that "has the potential to advance rapidly to a clinical trial."

A new feature of Vanderbilt's GI SPORE renewal application was the inclusion of patient advocates as integral members of each project.

"We're very proud that we have a strong group of patient advocates who are an integral part of our SPORE program," Coffey said. "They are always reminding us…how is this going to impact patients with colorectal cancer, either in terms of prevention, diagnosis or treatment. That's a good reality test.

"I think we're uniquely poised to make significant advances in these areas over the next five years."

GI SPORE projects and their leaders:The SPORE is supported by a number of "tremendous cores," Coffey said. These cores and their leaders are Administrative, Coffey, Rothenberg and Ann Greene; Tissue, Washington; Clinical Trials, Rothenberg; Biostatistics, Yu Shyr, Ph.D., and Bonnie LaFleur, Ph.D., M.P.H.; and High-Throughput Screening, Weaver, Michelle Lewis, Ph.D., and Emily Days.

"I can't emphasize enough how much of a team effort this was," Coffey said. "This renewal represents the tireless efforts of people like Jeffrey Franklin, Bonnie LaFleur and H. Charles Manning, who are really the unsung heroes of this process. They are three examples of the willingness of people to pull together and work toward a common goal, which is, I think, one of the real strengths of Vanderbilt."
-end-
The Vanderbilt-Ingram Cancer Center is Tennessee's only National Cancer Institute-designated Comprehensive Cancer Center and member of the National Comprehensive Cancer Network, a non-profit alliance of the world's leading cancer centers coming together to improve the quality of care for cancer patients everywhere. For more information, visit www.vicc.org.

Vanderbilt University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.